RELMADA THERAPEUTICS, INC. Lease, Cost
RELMADA THERAPEUTICS, INC. (RLMD) reported Lease, Cost of $6.55 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2022-03-25
- RELMADA THERAPEUTICS, INC. lease, cost for fiscal 2021 was $6.55K, a 24.97% decline from fiscal 2020.
- RELMADA THERAPEUTICS, INC. lease, cost for fiscal 2020 was $8.73K.
| Period end | Lease, Cost 6 month | Lease, Cost 12 month |
|---|---|---|
| 2021-12-31 | $6.55K 10-K · filed 2022-03-25 | |
| 2020-12-31 | $8.73K 10-K · filed 2021-03-24 | |
| 2019-12-31 | $13.61K 10-KT · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |